Treatment effect on 28-day mortality, by subgroup	Events int	No. int.	Events cont.	No. cont.	•	p–int*
High-flow or non-invasive ventilation, mechanical ventilation, ECMO	86	536	130	551		0.77
No ventilation at baseline: No or only low-flow oxygen	39	1096	63	1081		
No oxygen	1	184	4	206	-	0.76
Only low-flow oxygen	38	912	59	875		
High-flow or non-invasive ventilation	52	413	82	422	<u> </u>	
Mechanical ventilation or ECMO	34	123	48	129	<u> </u>	
70 years of age or older	58	314	82	320		0.23
Below 70 years of age	67	1320	111	1317	<u> </u>	
No comorbidity	13	366	20	383		0.78
One comorbidity	29	469	44	478		
Multiple comorbidities	77	758	127	738		
Immunocompromised	6	33	2	28	I	\rightarrow
No Dexamethasone, no Tocilizumab	9	215	24	232	<u> </u>	0.37
Dexamethasone, but no Tocilizumab	92	902	132	881	<u> </u>	
Enrolment more than 10 days after symptom onset	42	569	88	596	├──	0.58
Enrolment between 5 and 10 days after symptom onset	65	783	76	765	<u> </u>	
Enrolment 5 days or earlier after symptom onset	18	274	28	259	<u> </u>	
C-reactive protein 75mg/L or more	51	418	72	419	 	0.67
C-reactive protein less than 75mg/L	38	529	61	545	<u> </u>	
Overall treatment effect						
					0 0.25 0.5 0.75 1 1.25 1.5 Favours JAKi <-> Favours No JAKi	